AngioDynamics (NSDQ:ANGO) announced today that it launched the Auryon atherectomy system for treating peripheral artery disease (PAD). Latham, N.Y.-based AngioDynamics’ newly developed, FDA-cleared Auryon atherectomy system uses lasers to treat PAD lesions and occlusions, both above and below the knee in any type or length with minimal impact on the vessel walls, according to a news […]
AngioDynamics
AngioDynamics lands 510(k) for ‘smart’ implantable port
AngioDynamics (NSDQ:ANGO) announced today that it received FDA 510(k) clearance and CE Mark approval for its SmartPort+ implantable port product. SmartPort+ is an implantable, subcutaneous port for those who require long-term access to the central venous system for blood specimen withdrawal and administration of fluids, according to a news release. Latham, N.Y.-based AngioDynamics’ device utilizes the […]
MedTech 100 roundup: Industry hits pandemic peak
After five months since medtech stocks peaked before the COVID-19 pandemic rocked the markets, the industry inched back toward that pre-pandemic high. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 88.9 points at the end of last week (July 17). That total represents just a -3.7% […]
AngioDynamics slides on missed Q4 revenues
AngioDynamics (NSDQ:ANGO) posted fourth-quarter results that missed the consensus forecast on Wall Street. The company reported losses of -$156.1 million, or -$4.10 per share, on sales of $58.3 million for the three months ended May 31, for a sales loss of -18.1% compared with Q4 2019. Adjusted to exclude one-time items, earnings per share were -6¢, […]
AngioDynamics takes ‘interim’ out of CFO Trowbridge’s title
AngioDynamics (NSDQ:ANGO) announced that it removed the interim label from CFO Stephen Trowbridge’s title, making him the company’s permanent CFO while appointing him to the role of executive VP. Trowbridge had served as interim CFO since Oct. 22, 2019, and was officially placed in the role on Feb. 5, 2020. He also served as a senior […]
AngioDynamics starts postmarket study
AngioDynamics (NSDQ:ANGO) announced today that it launched a postmarket study of its Auryon atherectomy system for treating lesions in patients with peripheral artery disease (PAD). The Auryon atherectomy system, previously known as the Eximo B-Laser, is a wavelength laser technology platform that AngioDynamics acquired in October 2019. The system is designed to treat de novo, re-stenotic […]
AngioDynamics puts up $66m for Eximo Medical, cuts outlook
AngioDynamics (NSDQ:ANGO) said today that put up $66 million for Eximo Medical and its B-Laser peripheral atherectomy device and cut its fiscal 2020 earnings outlook to allow for the cost of launching the Eximo product. Latham, N.Y-based AngioDynamics said the deal for Eximo involved $46 million in up-front cash and another $20 million in technical and […]
Federal judge rules AngioDynamics may sue Canadian company
A federal judge has ruled that AngioDynamics (NSDQ:ANGO) may pursue a racketeering lawsuit against Canada-based Clarion Medical Technologies. The Clarion case stems from a decade-long dispute pitting Latham, N.Y.-based AngioDynamics against Austrian medical laser company Biolitec AG. AngioDynamics claims that Clarion laundered Biolitec group products to conceal revenues and prevent Biolitec from paying a $75 […]
AngioDynamics closes $168m sale of Namic assets to Medline Industries
AngioDynamics (NSDQ:ANGO) said yesterday that it closed the $167.5 million sale of its Namic fluid management portfolio to Medline Industries. The sale, originally announced in April, includes all of Latham, N.Y.-based AngioDynamic’s manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories offered under the Namic brand. AngioDynamics said that it has used […]
FDA OKs AngioDynamics trial for NanoKnife in prostate cancer
AngioDynamics (NSDQ:ANGO) today announced the FDA has approved its investigational device exemption application for its NanoKnife irreversible electroporation pilot study. The non-randomized pilot study will include six subjects at up to three sites and is designed to inform the design of a pivotal clinical study in the U.S. to help support the company’s bid for pre-market […]
AngioDynamics wins IRB approval for Stage 3 pancreatic cancer NanoKnife study
AngioDynamics (NSDQ:ANGO) said yesterday that it won central Institutional Review Board approval to run a clinical study of its NanoKnife irreversible electroporation system seeking an indication for use in treating Stage III pancreatic cancer. The Lantham, N.Y.-based company said that the approval will accelerate its engagement with local IRBs and will hasten its DIRECT clinical study. […]